The Covid-19 crisis has impelled the pharmaceutical companies to explore new strategies in a bid to address pandemic related clinical trial disruptions.
GlobalData conducted a survey to identify the key strategies that the companies are adopting to tackle clinical trial disruptions due to the coronavirus outbreak.
Go deeper with GlobalData
Addressing Clinical Trial Disruptions Related to the Covid-19 Outbreak
An analysis of the survey results shows that a signficant number of the companies have turned to remote patient monitoring (RPM) following new guidance from regulatory authorities that supported remote monitoring during the Covid-19 outbreak.
Approximately 17% of the respondents stated that they were switching to RPM, which involves monitoring clinical trial patients over phone, email or patient portal.
Another 15% were planning to move to decentralised/ virtual trials for future programmes, while 14% are exploring remote site initiation visits for critical trials.
Furthermore, 13% of the companies asked their research staff to work remotely, while 11% were adopting direct-to-patient (DTP) drug delivery.
A total of 9% of the respondents halted screening or enrolment for all clinical trials and another 7% stopped initiating any new trial.
The survey also found that 7% of the companies are prioritising enrolment for certain clinical trials and the remaining 7% were pursuing remote safety lab collections.
The analysis is based on responses received from the Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.
